Rock Weekly: FDA may win the battle, but 23andMe will win the war


January 6, 2013

Happy New Year from Rock Health! As the dust from fireworks settled and the bowties came off, we released our third annual and best ever Digital Health Funding Year in Review. Sink your teeth in. Also last week, IMS Health announced it’s going public (again) after filing for a $100M IPO.

We’re excited to welcome Factor 14, an intelligent anticoagulation management platform, to the Rock Health family! Factor 14 was named a finalist in Verizon’s Powerful Answers Award. The winner will be announced Wednesday at CES. Let’s go Factor 14!

Heading to CES? Us too. Here’s the rundown on where every digital health aficionado needs to be. We’ve also got two free passes to Robotics on the Runway at CES on Tuesday night. Tell us via Twitter what disruptive health bots you want to see to win your spot!


The FDA May Win The Battle, But 23andMe Will Win The War

I Had My DNA Picture Taken, With Varying Results
The New York Times

23andMe’s Anne Wojcicki On Accuracy Of Direct-To-Consumer DNA Tests
Fast Company

How Do You Measure Up? New Health Gadgets Can Tell You

Cancer Drugs: Getting Close And Personal
The Economist

Emergency Visits Seen Increasing With Health Law
The New York Times

The Best Disruptive Writings Of 2013 — Healthcare Edition

A Mind-Controlled Exoskeleton Will Kick Off The 2014 World Cup

Obamacare Is Confusing
The Atlantic


Company Amt Investors Source
MC10 $19.8M Undisclosed Boston Business Journal
DNAnexus $15M Claremont Creek Ventures, Google Ventures, TPG Biotech, First Round Capital MedCity News
GymPact $1.5M Khosla Ventures and Max Levchin TechCrunch

You’re missing out. Get the most talked about digital health rundown in your inbox.

    Rock Health will use the information you provide on this form to be in touch with you with news and occasional marketing.

    You can change your mind at any time by clicking the unsubscribe link at the bottom of our emails or by contacting We will treat your information with respect. By clicking below, you agree that we may process your info in accordance with these terms.